Our research center is dedicated to the research, development and progress of new therapies for a number of different disorders that will improve the quality of life for patients. We are continually enrolling patients of all ages in research studies. We may have a study that is right for you! Please look below at our currently enrolling studies. If interested, please fill out the form below or call us at 949-347-8700 x1800.

 

Currently Enrolling Studies

Migraines For Adults

Enrolling

Randomized, double-blind, multi-center, parallel-group, dose-ranging, comparison of the safety and efficacy of the ZP-Zolmitriptan intracutaenous microneedle systems to placebo for the acute treatment of migraine.

Asthma for Adults

Enrolling

The purpose of this study is to demonstrate the pharmacodynamics bioequivalence of the test product to the reference product, using bronchoprovocation (methacholine challenge testing) in adult patients with stable mild asthma

Food Allergy

Enrolling

Efficacy and safety of AR101

The purpose of this study is to demonstrate the efficacy and safety of AR101 through reduction in clinical reactivity to peanut allergen in peanut allergic children and adults.

 

Chronic Cough

Enrolling

A 12 week study to assess the efficacy and safety of AF219 in subjects with Refractory Chronic Cough

Urticaria

Enrolling

This is a placebo and active-controlled phase 2b dose-finding study to evaluate efficacy and safety of QGE031 monthly subcutaneous injections as add-on therapy in patients with Chronic Spontaneous Urticaria.

Allergic Rhinitis

Enrolling

Efficacy and Safety of STG320 Sublingual Tablets of House Dust Mite (HDM)

A Randomized, Double-Blind, Placebo Controlled Multi Center Study of the Efficacy and Safety of STG320 Sublingual Tablets of House Dust Mite (HDM) Allergen Extracts in Adults & Adolescents with HDM associated allergic rhinitis.

Asthma for Adolescent and Adult Patients

Enrolling

Evaluation of Dupilumab in Patients With Persistent Asthma

Primary Objective: To evaluate the efficacy of dupilumab in patients with persistent asthma.

Secondary Objectives: To evaluate the safety and tolerability of dupilumab. To evaluate the effect of dupilumab in improving patient-reported outcomes including health-related quality of life. To evaluate dupilumab systemic exposure and incidence of antidrug antibodies.

12 years and older

Both Male & Female

 

Enrolling

A Randomized, Double-Blind, Placebo Controlled Parallel Group Study to Evaluate the Efficacy and Safety of Dupilumab in Patients with Persistent Asthma.

12 years and older

Both Male & Female

 

Enrolling

The primary objective of the study is to evaluate the protective effect of fluticasone furoate/vilanterol (FF/VI) 100/25 mcg once-daily compared with fluticasone propionate (FP) 250 mcg twice-daily against exercise-induced bronchoconstriction in adolescent and adult subjects aged 12 to 50 with persistent asthma

Asthma for Adolescents

Enrolling

A Study of Lebrikizumab in Adolescent Patients With Uncontrolled Asthma Who Are on Inhaled Corticosteroids and a Second Controller Medication

This randomized, multicenter, double-blind, placebo-controlled, parallel-group study will evaluate the efficacy, safety and tolerability of lebrikizumab in adolescent patients with asthma whose disease remains uncontrolled despite daily treatment with inhaled corticosteroid therapy and at least one second controller medication. Patients will be randomized 1:1:1 to receive double-blind treatment with either lebrikizumab ("high" or "low") or placebo, administered subcutaneously (SC) every 4 weeks for 52 weeks, in addition to their standard-of-care therapy. This will be followed by a 52-week double-blind active treatment extension. The anticipated time on study treatment up to 104 weeks. After study treatment, all patients will complete a 20 week safety follow-up.

12 Years to 17 Years

Both Male & Female

Chronic Cough for Adults

Enrolling

A Dose Escalation Study of AF-219 in Refractory Chronic Cough

A randomized, double-blind, placebo-controlled, crossover, dose escalation study of AF-219 in subjects with Refractory Chronic Cough.

18 Years to 80 Years

Both Male & Female

 

Active Non-Enrolling Studies

Asthma for Adults

No Current Active Studies

 

 

Completed Studies

Asthma for Children

Completed

A Safety and Efficacy Study of Beclomethasone Dipropionate Delivered Via Breath-Actuated Inhaler (BAI) or Metered-Dose Inhaler (MDI) in Participants Ages 4-11 Years Old With Persistent Asthma

This randomized, double-blind, double-dummy, placebo-controlled, parallel-group, 12-week study will evaluate the efficacy and safety of beclomethasone dipropionate (80 or 160 mcg/day) administered via breath-actuated inhaler (BAI) and metered-dose inhaler (MDI) in pediatric patients 4 through 11 years of age with persistent asthma, compared with placebo.

4 to 11 years

Both Male and Female

 

Completed

A 12-Week Study in Asthmatic Children Ages 6 to <12

The purpose is to investigate the efficacy and safety of Symbicort pMDI 80/2.25 μg and Symbicort pMDI 80/4.5 μg, compared with Budesonide pMDI 80 μg, 2 Actuations twice daily, in children ages 6 to <12 years with asthma during 12 weeks.
6 to 11 years

Both Male & Female

 

 

Asthma for Adolescent and Adult Patients

Completed

Efficacy and Safety Study of FP MDPI Compared With FS MDPI in Adolescent and Adult Patients With Persistent Asthma

Study drug and placebo will be supplied in Teva multidose dry powder inhaler (MDPI) devices and provided for participants to use at home. Participants will perform spirometry at every visit. Each participant will be given a diary at each visit for use until the next visit. Rescue medication (albuterol/salbutamol) will be dispensed at each visit, if needed, as determined by the investigational center personnel.

12 Years and older

Both Male & Female

 

Completed

Long-Term Safety Study of Fluticasone Propionate (Fp) Multidose Dry Powder Inhaler (MDPI) and Fluticasone Propionate/Salmeterol (FS) MDPI in Patients With Persistent Asthma

The primary objective of the study is to evaluate the long-term safety of fluticasone propionate inhalation powder in 2 strengths and fluticasone propionate/salmeterol inhalation powder in 2 strengths when administered with the Teva MDPI device over 26 weeks in patients with persistent asthmaLong-Term Safety Study of Fluticasone Propionate (Fp) Multidose Dry Powder Inhaler (MDPI) and Fluticasone Propionate/Salmeterol (FS) MDPI in Patients With Persistent Asthma

12 Years and older

Both Male & Female

 

Completed

Study to Assess the Efficacy and Safety of Beclomethasone Dipropionate in Adolescent and Adult Patients 12 Years of Age and Older With Persistent Asthma

The primary objective of this study is to evaluate the efficacy of beclomethasone dipropionate administered via BAI at a dose strength of 40 or 80 mcg per oral inhalation (320 or 640 mcg/day, respectively) compared with placebo treatment in patients with persistent asthma as assessed by the standardized baseline-adjusted trough morning (pre-dose and pre-rescue bronchodilator).

12 years and older

Both Male and Female

 

Completed

Study of Fluticasone Propionate MDPI Compared With Fluticasone/Salmeterol MDPI in Adolescent and Adult Patients With Persistent Asthma

Study drug and placebo will be supplied in Teva multidose dry powder inhaler (MDPI) devices and provided for participants to use at home. Participants will perform spirometry at every visit. Each participant will be given a diary at each visit for use until the next visit. Rescue medication (albuterol/salbutamol) will be dispensed at each visit, if needed, as determined by the investigational center personnel.

12 Years and older

Both Male & Female

 

Asthma for Adults

 

Completed

A Study of JNJ-38518168 in Symptomatic Adult Participants With Uncontrolled, Persistent Asthma

The purpose of this study is to evaluate the efficacy, safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of JNJ-38518168 compared with placebo in participants with persistent asthma that is inadequately controlled despite current treatment.

18 Years to 75 Years

Both Male & Female

 

Completed

Crossover Study to Evaluate the Efficacy, Safety and Tolerability of Different Doses of Indacaterol in Patients With Persistent Asthma (QAB149)

The purpose of this study is to determine the efficacy of indacaterol 55µg once daily (and 27.5 µg twice) in QVA149 compared to 75 µg indacaterol monotherapy.

18 Years and older

Both Male & Female

 

Completed

An Evaluation of Dupilumab in Patients With Moderate to Severe Uncontrolled Asthma

Primary objective: To evaluate the efficacy of different doses and regimens of dupilumab in patients with moderate to severe, uncontrolled asthma Secondary objective: To evaluate different doses and regimens of dupilumab in patients with moderate to severe uncontrolled asthma, with regard to: Safety and tolerability Dupilumab systemic exposure and anti-drug antibodies

18 Years and older

Both Male & Female

 

Completed

Advair Diskus Local Equivalence Study in Asthma

The purpose of this study is to determine whether MGR001 is equivalent to Advair Diskus when administered by inhalation in adult asthma patients.

18 Years and older

Both Male & Female

 

Completed

Clinical Efficacy Study of Salmeterol Xinafoate/Fluticasone Propionate in Asthma

This is a study to establish the equivalence of OT329 Solis and Advair Diskus when administered by inhalation in patients with asthma.

18 Years and older

Both Male & Female

 

Completed

A Study to Assess the Effect of QAW039 in Non-atopic Asthmatic Patients

The purpose of the study is to assess the clinical effect of QAW039 in non-atopic asthmatics taking low dose Inhaled Corticosteroid (ICS) as background therapy.

18 Years and older

Both Male & Female

 

Atopic Dermatitis for Adults

Completed

Adult Patients with Atopic Dermatitis

The primary objective for this study is to evaluate the safety of lebrikizumab compared with Topical Corticosteroids (TCS) alone in patients with persistent moderate to severe Atopic Dermatitis (AD) that is inadequately controlled with TCS.

18 Years to 75 Years

Both Male & Female

 

Completed

Study of Dupilumab and Immune Responses in Adults With Atopic Dermatitis (AD)

This is a 32-week, randomized, double-blind, placebo-controlled, parallel-group study assessing immunization responses to vaccination in adults with moderate to severe atopic dermatitis who are treated with subcutaneous dupilumab.

18 Years to 64 Years

Both Male & Female

Dust Mite for Adolescent and Adult Patients

Completed

Long-Term Efficacy and Safety Study of SCH 900237/MK-8237 in Children and Adults With House Dust Mite-Induced Allergic Rhinitis/Rhinoconjunctivitis (P05607)

The purpose of this study is to assess the efficacy and safety of MK-8237 (SCH 900237) in the treatment of House Dust Mite (HDM)-Induced Allergic Rhinitis/Rhinoconjunctivitis (AR/ARC) in children and adults. The primary hypothesis of this study is that administration of MK-8237, compared to placebo, results in significant reduction in the average total combined rhinitis score (TCRS).

12 Years and older

Both Male & Female

Chronic Idiopathic Urticaria (Chronic Hives) for Adolescent and Adult Patients

Completed

A Study to Assess the Efficacy and Safety of Omalizumab Through 48 Weeks in Participants With Chronic Idiopathic Urticaria (CIU)

This randomized, double-blind, placebo-controlled study will evaluate efficacy and safety of subcutaneous omalizumab as an add-on therapy through 48 weeks. After completing an initial 24-week open-label treatment period with omalizumab 300 mg every 4 weeks, participants responding to omalizumab will be randomized at a 3:2 ratio (omalizumab:placebo) to either continue omalizumab or be transitioned to placebo for a further 24 weeks.

12 years to 75 years

Both Male & Female

 

Completed

Dose-finding Study of QGE031 as add-on Therapy to Evaluate Efficacy and Safety in Patients With Chronic Spontaneous Urticaria.

This is a placebo and active-controlled phase 2b dose-finding study to evaluate efficacy and safety of QGE031 monthly subcutaneous injections as add-on therapy in patients with Chronic Spontaneous Urticaria.

18 years to 75 years

Both Male & Female 

Cow’s Milk Allergy for Children

Completed

Evaluation of Hypoallergenicity of a New Extensively Hydrolyzed Formula

Infants/children with cow's milk allergy will take part in 2 double-blinded placebo-controlled food challenges of 2 extensively hydrolyzed formulas in random order. If both food challenges are passed, subjects will be asked to consume the test formula in an at-home open challenge for 7 days.

2 Months to 4 Years

Both Male & Female

Rhinoconjunctivitis for Adults

Completed

Phase II HDM-SPIRE Safety and Efficacy Study

The purpose of this study is to compare the treatment effect of three treatment regimens of HDM-SPIRE vs placebo and to evaluate the treatment effect of HDM-SPIRE on symptoms, rescue medication usage, quality of life and sleep quality.

18 Years to 65 Years

Both Male & Female

 

 

What's New

Can peanut allergy be prevented by introducing peanut early?

The question of when to introduce peanut is one that many of my patients and friends ask me. I asked myself the same question when I had my first baby girl.  At the time, I was completing a fellowship in allergy/immunology. There was no obvious answer based on the studies that had been done.  I would tell patients, “there is not strong evidence either way; do what makes you comfortable. I can...Read More

 
app store

What Our Patients Say About Us

  • I couldn’t breathe, I couldn’t do anything that I wanted to do, let alone go out and do anything athletic with my children or for myself. Then I met Dr Berger. He changed my life – he put in the time, the effort and the extra research to get me the diagnosis and the correct medications that changed my life forever!... - Linda

  • When I first got diagnosed with asthma it started off as exercised induced but throughout the years it became worse than that. Just a wind would make me feel like I needed to take my inhaler, a change in the weather and I had to take a breathing treatment. It was really hard especially for being an athlete, because you don’t want anything holding you back from what you love to do...

 
 

Three Locations to Serve You!

 

27800 Medical Center Road
Suite 244
Mission Viejo, CA 92691

675 Camino de Los Mares
Suite 403
San Clemente, CA 92673

15785 Laguna Canyon Road
Suite 100
Irvine, CA 92618

Get In Touch

Copyright © 2014 Practice Builders and Allergy & Asthma Associates of Southern California. All rights reserved.